Six stages. Each one produces something you can show an investor.
The first four stages answer what the company is worth and why. The last two answer what price you can hold, and how you hold it.

Runway, burn, and the capital-optional test. Whether you can walk away sets how firm a price you can hold, so it is the first thing we establish rather than the last.
Twenty milestones across clinical, regulatory, technical, commercial, and capital, weighted by device class and stage. The output is your WRXS and the single risk dimension that dominates how investors read you.
Most decisions do not move enterprise value. We isolate the two or three that are irreversible, timing-critical, and consequential across more than one risk area — and set the rest aside.
What the company is worth today, and what band it prices into once the next milestone clears. Keyed to device class, regulatory pathway, and milestone stage — not to “companies like us.”
The clearance probability with its evidence build-up, the downside case, and the price your evidence supports for your instrument — cap, pre-money, or conversion terms. Plus what each level costs you in dilution and where your walk-away sits.
The objections you will face at your stage, the evidence-based answer to each, and whether to raise before or after the decision in front of you.
Written readout within ten business days of receiving complete information.
Ninety-minute working session within five business days of delivery.
Payment due half on signature, half on delivery.
Founding-client term: if you do not use the readout in a live financing conversation, the second half is refunded on request.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.